REGENXBIO Inc. (RGNX) · Oct 16, 2026 · Control change

REGENXBIO board change shifts chair as founder exits

Chairman change — Mills resigns; Migausky appointed chairman

REGENXBIO’s board change removes founder Kenneth Mills and names George Migausky chairman, preserving an independent chair during a pivotal pipeline year.

REGENXBIO is a late-stage gene-therapy company moving toward potential commercialization across Duchenne, retinal disease and other rare-disease programs, with multiple clinical and regulatory milestones planned for 2026. The filing changes governance, not the operating plan. Kenneth T. Mills, the company’s founder and former CEO, is leaving the board effective October 21, 2026 to focus on becoming CEO of another company. 〔0〕 That removes a founder-level presence just as REGENXBIO is navigating the shift from clinical development toward commercial execution, but the filing does not signal any change to programs, strategy or management. The succession is orderly and preserves board independence. George Migausky, already an independent director, becomes chairman, while Daniel Tassé leaves the lead independent director role because that position is no longer needed under the company’s governance guidelines. 〔1〕 〔2〕 The company also explicitly says Mills’ departure was unrelated to any disagreement, which makes this read as a personal transition rather than an operating or governance dispute. 〔3〕 Bottom line: This is a real leadership change but a low-substance business event: REGENXBIO loses its founder from the board, while an independent director takes over without altering the company’s gene-therapy execution story. Sources indicate Mills had already been serving as CEO of another biotech, so the filing formalizes a transition more than it introduces a strategic surprise.

Original filing on SEC EDGAR

More REGENXBIO Inc. news

REGENXBIO board change shifts chair as founder exits | RGNX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.